PDGFRA and colorectal carcinoma: In that same study, a xenograft model carrying the PDGFRA R981H mutation treated with imatinib in combination with cetuximab showed increased efficacy, suggesting that PDGFRA kinase inhibitors might be useful for treating cetuximab-resistant CRC.